Viridian Therapeutics, Inc. $VRDN Shares Acquired by Squarepoint Ops LLC

Squarepoint Ops LLC grew its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 303.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 176,955 shares of the company’s stock after buying an additional 133,046 shares during the period. Squarepoint Ops LLC’s holdings in Viridian Therapeutics were worth $3,251,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. California State Teachers Retirement System grew its holdings in shares of Viridian Therapeutics by 1,972.4% during the second quarter. California State Teachers Retirement System now owns 1,679,055 shares of the company’s stock valued at $30,844,000 after buying an additional 1,598,034 shares during the last quarter. Perceptive Advisors LLC raised its stake in Viridian Therapeutics by 108.1% in the 4th quarter. Perceptive Advisors LLC now owns 3,042,703 shares of the company’s stock worth $94,689,000 after acquiring an additional 1,580,303 shares during the last quarter. Morgan Stanley raised its stake in Viridian Therapeutics by 805.6% in the 4th quarter. Morgan Stanley now owns 1,738,225 shares of the company’s stock worth $54,094,000 after acquiring an additional 1,546,284 shares during the last quarter. Avoro Capital Advisors LLC acquired a new stake in Viridian Therapeutics during the 4th quarter worth about $46,680,000. Finally, Parkman Healthcare Partners LLC acquired a new stake in Viridian Therapeutics during the 2nd quarter worth about $25,306,000.

Insiders Place Their Bets

In other Viridian Therapeutics news, insider Jennifer Tousignant sold 14,212 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $24.50, for a total value of $348,194.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.40% of the company’s stock.

Viridian Therapeutics Price Performance

Shares of NASDAQ VRDN opened at $21.24 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 16.95 and a quick ratio of 16.95. The stock has a market capitalization of $2.41 billion, a price-to-earnings ratio of -6.30 and a beta of 0.97. The firm’s 50 day simple moving average is $21.47 and its 200-day simple moving average is $20.34. Viridian Therapeutics, Inc. has a 12 month low of $13.18 and a 12 month high of $34.29.

Viridian Therapeutics (NASDAQ:VRDN) last posted its earnings results on Thursday, August 6th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by ($0.02). Viridian Therapeutics had a negative net margin of 505.86% and a negative return on equity of 72.97%. The firm had revenue of $0.28 million during the quarter, compared to analyst estimates of $0.06 million. Analysts expect that Viridian Therapeutics, Inc. will post -4.07 EPS for the current year.

Analyst Upgrades and Downgrades

VRDN has been the topic of a number of research reports. Wells Fargo & Company raised Viridian Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $20.00 to $31.00 in a report on Monday, June 29th. Wall Street Zen downgraded Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. Royal Bank Of Canada upped their target price on Viridian Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a research report on Friday, August 7th. Needham & Company LLC reiterated a “buy” rating and issued a $32.00 price target on shares of Viridian Therapeutics in a report on Monday, June 29th. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $39.00 price target on shares of Viridian Therapeutics in a research report on Tuesday, June 30th. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $38.54.

About Viridian Therapeutics

Viridian Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious diseases involving the immune system. The company’s primary focus is thyroid eye disease (TED), an autoimmune disorder that can cause inflammation, pain, swelling and vision-related complications.

Viridian’s lead programs target the insulin-like growth factor 1 receptor (IGF-1R), a pathway associated with TED. Its pipeline has included investigational therapies such as veligrotug (VRDN-001), an intravenous antibody designed to block IGF-1R, and subcutaneous formulations intended to provide more convenient administration.